Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESH CLL 2020 | Key questions about the future of CLL

Florence Cymbalista • 17 Nov 2020
ESH CLL 2020
Chronic Lymphocytic Leukemia Leukemia

Florence Cymbalista, MD, PhD, Avicenne Hospital, Bobigny, France, poses key questions about the future of chronic lymphocytic leukemia (CLL) treatment, including how treatments should be sequenced, as well as a greater understanding of resistance mechanisms. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Florence Cymbalista

Towards strategies to optimize outcomes in CLL
2:30
Towards strategies to optimize outcomes in CLL
Florence Cymbalista • 7 Oct 2022
Moving towards time-limited treatment in frontline CLL
2:07
Moving towards time-limited treatment in frontline CLL
Florence Cymbalista • 7 Oct 2022
The importance of TP53 & IGHV testing before treatment initiation in CLL
2:27
The importance of TP53 & IGHV testing before treatment initiation in CLL
Florence Cymbalista • 7 Oct 2022
Challenges in interpreting the results of genomic tests in CLL
1:33
Challenges in interpreting the results of genomic tests in CLL
Florence Cymbalista • 7 Oct 2022

Related Videos

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Florence Cymbalista • 24 Nov 2025
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
1:16
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
Florence Cymbalista • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Florence Cymbalista • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Florence Cymbalista • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals